Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Musculoskeletal

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Remission · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

It is very uncertain whether infliximab changes remission compared with rituximab (very low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 0.44 [0.11, 1.81]
Studies not reported
Very low

Durable remission during additional · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

It is very uncertain whether infliximab changes durable remission during additional compared with rituximab (very low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 0.22 [0.03, 1.6]
Studies not reported
Very low